Energenesis Biomedical Co., Ltd.(TW:6657)
NT$30.000.00 (0.00%)
TW:6657
Energenesis Biomedical Co., Ltd. financials statements
NT$30.00
At close:0.00 (0.00%)
Energenesis Biomedical Co., Ltd. (6657) Ratios
Energenesis Biomedical Co., Ltd. Ratios
TW:6657's free cash flow for Q2 2026 was NT$-96.33M. For the 2026 fiscal year, TW:6657's free cash flow was decreased by NT$-432.00K and operating cash flow was NT$-95.90M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 19.91 | 19.19 | 33.71 | 20.67 | 27.16 |
| Quick Ratio | 19.89 | 19.17 | 33.67 | 20.64 | 27.14 |
| Cash Ratio | 15.50 | 11.29 | 11.55 | 3.70 | 5.48 |
| Solvency Ratio | -4.47 | -5.04 | -9.62 | -8.52 | -2.91 |
| Operating Cash Flow Ratio | -5.12 | -5.04 | -10.54 | -9.56 | -3.57 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | NT$ 811.72M | NT$ 646.44M | NT$ 694.86M | NT$ 475.18M | NT$ 706.55M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.01 | 0.01 | 0.02 | 0.01 |
| Debt-to-Equity Ratio | 0.02 | 0.01 | 0.01 | 0.02 | 0.01 |
| Debt-to-Capital Ratio | 0.02 | 0.01 | 0.01 | 0.02 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.06 | 1.06 | 1.03 | 1.05 | 1.04 |
| Debt Service Coverage Ratio | -545.80 | -981.43 | -1112.22 | -1153.31 | -341.73 |
| Interest Coverage Ratio | -594.55 | -1203.63 | -1223.54 | -1270.12 | -422.37 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.17 | 0.13 | 0.12 | 0.15 | 0.20 |
| Net Debt to EBITDA | 2.60 | 1.90 | 1.00 | 0.33 | 1.42 |
| Profitability Margins | |||||
| Gross Profit Margin | 76.00% | 73.43% | 73.02% | 70.26% | 71.56% |
| EBIT Margin | -3587.11% | -2979.33% | -3657.96% | -3611.14% | -1601.71% |
| EBITDA Margin | -3292.99% | -2685.03% | -3325.17% | -3279.04% | -1295.90% |
| Operating Profit Margin | -3587.11% | -3292.93% | -3657.96% | -3611.14% | -1601.71% |
| Pretax Profit Margin | -3367.24% | -2982.06% | -3637.64% | -3613.98% | -1605.50% |
| Net Profit Margin | -3367.24% | -2982.06% | -3637.64% | -3613.98% | -1605.50% |
| Continuous Operations Profit Margin | -3367.24% | -2982.06% | -3637.64% | -3613.98% | -1605.50% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 93.87% | 90.56% | 99.44% | 100.08% | 100.24% |
| Return on Assets (ROA) | -27.23% | -29.60% | -31.43% | -42.11% | -13.57% |
| Return on Equity (ROE) | -28.83% | -31.26% | -32.39% | -44.09% | -14.11% |
| Return on Capital Employed (ROCE) | -30.40% | -34.26% | -32.44% | -43.77% | -13.97% |
| Return on Invested Capital (ROIC) | -30.21% | -34.05% | -32.24% | -43.37% | -13.88% |
| Return on Tangible Assets | -27.26% | -30.13% | -32.46% | -44.88% | -14.41% |
| Earnings Yield | -6.79% | -5.93% | -5.86% | -5.97% | -3.00% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.89 | 3.88 | 4.56 | 4.34 | 5.33 |
| Payables Turnover | 4.69 | 6.62 | 5.66 | 5.91 | 7.20 |
| Inventory Turnover | 2.04 | 2.75 | 2.63 | 3.93 | 3.09 |
| Fixed Asset Turnover | 0.10 | 0.10 | 0.09 | 0.09 | 0.08 |
| Asset Turnover | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Working Capital Turnover Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Cash Conversion Cycle | 294.12 | 171.89 | 154.10 | 115.22 | 135.77 |
| Days of Sales Outstanding | 193.06 | 94.06 | 80.01 | 84.16 | 68.43 |
| Days of Inventory Outstanding | 178.93 | 132.95 | 138.55 | 92.84 | 118.07 |
| Days of Payables Outstanding | 77.87 | 55.13 | 64.46 | 61.78 | 50.72 |
| Operating Cycle | 371.99 | 227.02 | 218.56 | 177.00 | 186.50 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.51 | -2.36 | -3.13 | -3.49 | -1.62 |
| Free Cash Flow Per Share | -2.54 | -2.37 | -3.14 | -3.59 | -1.77 |
| Dividend Paid and CapEx Coverage Ratio | -96.36 | -239.67 | -266.65 | -35.35 | -10.94 |
| Capital Expenditure Coverage Ratio | -96.36 | -239.67 | -266.65 | -35.35 | -10.94 |
| Operating Cash Flow Coverage Ratio | -14.99 | -18.02 | -27.18 | -24.42 | -8.15 |
| Operating Cash Flow to Sales Ratio | -28.98 | -23.32 | -31.44 | -31.67 | -12.99 |
| Free Cash Flow Yield | -5.91% | -4.66% | -5.08% | -5.38% | -2.65% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -14.73 | -16.88 | -17.07 | -16.74 | -33.40 |
| Price-to-Sales (P/S) Ratio | 495.86 | 502.51 | 621.01 | 605.50 | 535.66 |
| Price-to-Book (P/B) Ratio | 4.25 | 5.27 | 5.53 | 7.39 | 4.71 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -16.93 | -21.46 | -19.68 | -18.59 | -37.78 |
| Price-to-Operating Cash Flow Ratio | -17.11 | -21.55 | -19.75 | -19.12 | -41.23 |
| Price-to-Earnings Growth (PEG) Ratio | 4.93 | 1.00 | 1.84 | -0.17 | 3.85 |
| Enterprise Value Multiple | -12.45 | -16.82 | -17.67 | -18.13 | -39.92 |
| Enterprise Value | 3.15B | 3.50B | 4.21B | 4.37B | 3.87B |
| EV to EBITDA | -12.45 | -16.82 | -17.67 | -18.13 | -39.92 |
| EV to Sales | 410.08 | 451.60 | 587.72 | 594.53 | 517.31 |
| EV to Free Cash Flow | -14.00 | -19.28 | -18.62 | -18.25 | -36.49 |
| EV to Operating Cash Flow | -14.15 | -19.36 | -18.69 | -18.77 | -39.82 |
| Tangible Book Value Per Share | 10.12 | 9.47 | 10.81 | 8.46 | 13.34 |
| Shareholders’ Equity Per Share | 10.13 | 9.65 | 11.18 | 9.04 | 14.19 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.09 | 0.10 | 0.10 | 0.11 | 0.12 |
| Net Income Per Share | -2.92 | -3.01 | -3.62 | -3.99 | -2.00 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.94 | 1.00 | 0.99 | 1.00 | 1.00 |
| Research & Development to Revenue | 23.69 | 23.21 | 25.86 | 29.07 | 8.25 |
| SG&A to Revenue | 10.00 | 10.45 | 11.45 | 8.59 | 8.77 |
| Stock-Based Compensation to Revenue | 2.29 | 1.92 | 2.08 | 1.51 | 0.66 |
| Income Quality | 0.86 | 0.78 | 0.86 | 0.88 | 0.81 |
Currency in TWD
